S&P 500 Futures
(0.15%) 5 139.00 points
Dow Jones Futures
(0.10%) 38 481 points
Nasdaq Futures
(0.23%) 17 886 points
Oil
(-0.36%) $83.55
Gas
(1.72%) $1.956
Gold
(0.28%) $2 353.80
Silver
(0.54%) $27.69
Platinum
(1.61%) $936.95
USD/EUR
(-0.14%) $0.933
USD/NOK
(-0.28%) $10.99
USD/GBP
(-0.29%) $0.798
USD/RUB
(1.18%) $92.96

Actualizaciones en tiempo real para Prescient Therapeutics [PTX.AX]

Bolsa: ASX Industria: Pharmaceuticals, Biotechnology & Life Sciences
Última actualización29 abr 2024 @ 02:10

0.00% $ 0.0520

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 02:10):
Profile picture for Prescient Therapeutics Ltd

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations...

Stats
Volumen de hoy 762 848
Volumen promedio 1.17M
Capitalización de mercado 41.88M
EPS $0 ( 2024-02-21 )
Last Dividend $7.15 ( 1993-10-21 )
Next Dividend $0 ( N/A )
P/E -5.20
ATR14 $0.00100 (1.89%)

Prescient Therapeutics Correlación

10 Correlaciones Más Positivas
10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Prescient Therapeutics Finanzas

Annual 2023
Ingresos: $2.43M
Beneficio Bruto: $2.43M (99.91 %)
EPS: $-0.00960
FY 2023
Ingresos: $2.43M
Beneficio Bruto: $2.43M (99.91 %)
EPS: $-0.00960
FY 2022
Ingresos: $1.89M
Beneficio Bruto: $1.89M (99.93 %)
EPS: $-0.00790
FY 2021
Ingresos: $0.00
Beneficio Bruto: $0.00 (0.00 %)
EPS: $-0.00680

Financial Reports:

No articles found.

Prescient Therapeutics Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Prescient Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $5.72 1990-10-25
Last Dividend $7.15 1993-10-21
Next Dividend $0 N/A
Payout Date 1993-12-31
Next Payout Date N/A
# dividends 2 --
Total Paid Out $12.87 --
Avg. Dividend % Per Year 0.00% --
Score 0.22 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2026-10-05)
$0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
0.22
Pay Frequency
Sporadic
Yearly Payout
Year Amount Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
MYS.AX Ex Dividend Junior 2023-08-23 Annually 0 0.00%
WGB.AX Ex Dividend Junior 2023-10-12 Semi-Annually 0 0.00%
ENN.AX No Dividend Player 2023-06-29 Annually 0 0.00%
PE1.AX Ex Dividend Junior 2023-07-03 Semi-Annually 0 0.00%
AMH.AX Ex Dividend Knight 2023-08-04 Annually 0 0.00%
GWA.AX Ex Dividend Knight 2023-08-18 Semi-Annually 0 0.00%
RHI.AX No Dividend Player 2023-07-10 Annually 0 0.00%
BSE.AX Ex Dividend Junior 2023-09-08 Semi-Annually 0 0.00%
LBL.AX Ex Dividend Knight 2023-09-07 Semi-Annually 0 0.00%
STO.AX Ex Dividend Knight 2023-08-28 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-2.491.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.3131.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-0.3181.500-4.65-6.97[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM10.260.80010.008.00[1 - 3]
quickRatioTTM9.960.80010.008.00[0.8 - 2.5]
cashRatioTTM3.081.50010.0010.00[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM01.000-1.111-1.111[3 - 30]
operatingCashFlowPerShareTTM-0.009522.00-0.00317-0.00635[0 - 30]
freeCashFlowPerShareTTM-0.009522.00-0.00476-0.00952[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM1.0001.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM-3.711.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM0.1260.800-2.50-1.996[0.5 - 2]
Total Score-0.920

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-5.511.000-0.6580[1 - 100]
returnOnEquityTTM-0.3182.50-2.99-6.97[0.1 - 1.5]
freeCashFlowPerShareTTM-0.009522.00-0.00317-0.00952[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.009522.00-0.00317-0.00635[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-1.9111.500-10.000[0.5 - 2]
operatingCashFlowSalesRatioTTM-2.461.000-10.000[0.1 - 0.5]
Total Score-2.81

Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico